Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background MRI-targeted biopsies are recommended for prostate cancer diagnosis. In-bore MRI-targeted biopsy enables high-precision needle placement; however, the factors affecting prostate cancer detection rates and the potential for grade and patient risk migration require further investigation. Purpose To evaluate factors affecting the detection rate of prostate cancer in patients who underwent in-bore MRI-targeted biopsy and their influence on histologic concordance between biopsy (bGG) and surgical grade group (sGG). Materials and Methods This retrospective study evaluated in-bore MRI-targeted biopsies performed between March 2015 and January 2023. The agreement between bGG and sGG was assessed using Cohen weighted κ. The detection rate of prostate cancer and the concordance rates between bGG and sGG in patients undergoing prostatectomy were compared between biopsy systems (manual and robotic) and by patient biopsy status, lesion size (≤10 mm vs >10 mm), and Prostate Imaging Reporting and Data System (PI-RADS) category. Results In total, 780 lesions (patient median age, 65 years [IQR, 59-70 years]) were included. Among patients with previous negative biopsy and biopsy-naive patients, the detection rates of grade group (GG) 2 or higher cancer were higher in patients with PI-RADS category 4 or higher lesions (42.5% and 46.5%) and lesions larger than 10 mm (45.1% and 43.4%) ( < .05). Surgical upgrading was higher in lesions with bGG 1 than in those with bGG 2-4 cancers (66.1% vs 16.0% [ < .001]). In the 216 patients undergoing radical prostatectomy, bGG and sGG showed moderate to substantial agreement (weighted κ correlation coefficient, 0.61 [95% CI: 0.51, 0.71]). A downgrade of two or more grades between bGG and sGG was rare (5.7%). Histopathologic concordance did not depend on the PI-RADS category, target lesion size, biopsy system, or patient biopsy status ( = .90). Conclusion The in-bore MRI-targeted biopsy detection rates for GG 2 or higher prostate cancer depend on the target lesion size and PI-RADS category, and there is a substantial risk of histologic upgrades in men with GG 1 lesions at MRI-targeted biopsy. © RSNA, 2025 See also the editorial by Milot in this issue.

Download full-text PDF

Source
http://dx.doi.org/10.1148/radiol.241710DOI Listing

Publication Analysis

Top Keywords

prostate cancer
24
in-bore mri-targeted
20
mri-targeted biopsy
20
bgg sgg
16
pi-rads category
16
detection rates
12
lesion size
12
biopsy
11
cancer diagnosis
8
mri-targeted biopsies
8

Similar Publications

This narrative review analyzes current evidence comparing single-session and two-session approaches in Stereotactic Body Radiation Therapy (SBRT) and high-dose-rate (HDR) brachytherapy for localized prostate cancer. These ultra-hypofractionated strategies deliver high-precision ablative doses while minimizing exposure to normal tissues. SBRT regimens with fewer than five fractions show tumor control comparable to conventional treatments, offering reduced treatment burden and increased convenience.

View Article and Find Full Text PDF

Purpose: Screening and diagnosing ISUP ≥ 2 prostate cancer is challenging. This study aimed to determine whether canine detection could be beneficial addition to the ISUP ≥ 2 prostate cancer diagnostic protocol by creating a decision-making algorithm for men with suspected prostate cancer.

Methods: We conducted a prospective study at two urology institutions and a French veterinary school, including men with a suspicion of prostate cancer from November to April 2023, which were divided into two groups according to their prostate biopsy results.

View Article and Find Full Text PDF

Background: The optimal management of synchronous rectal cancer (RC) and prostate cancer (PC) remains unclear. This systematic review evaluates treatment strategies and reports postoperative, oncological, and quality-of-life outcomes in patients treated with curative intent.

Methods: Following PRISMA guidelines, this systematic review was registered in PROSPERO (CRD42024598049).

View Article and Find Full Text PDF

Neural activity is increasingly recognized as a crucial regulator of cancer growth. In the brain, neuronal activity robustly influences glioma growth through paracrine mechanisms and by electrochemical integration of malignant cells into neural circuitry via neuron-to-glioma synapses. Outside of the central nervous system, innervation of tumours such as prostate, head and neck, breast, pancreatic, and gastrointestinal cancers by peripheral nerves similarly regulates cancer progression.

View Article and Find Full Text PDF